*Department of Clinical Pharmacology, University Medical Center Göttingen, Göttingen, Germany;
†Department of Nephrology and Intensive Care, Charité—Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany; and
‡Chronix Biomedical GmbH, Göttingen, Germany.
Correspondence: Michael Oellerich, MD, Georg-August-University, University Medical Center, Kreuzbergring 36, D-37075 Göttingen, Germany (e-mail: [email protected]).
M. Oellerich acts as a consultant to Oncocyte (Irvine, California). K. Bornemann-Kolatzki, J. Beck, and E. Schütz are employees of Chronix Biomedical GmbH, a subsidiary of Chronix Biomedical Inc (an Oncocyte company), which holds intellectual property rights (EP 3004388B1, EP3201361B1, and US10570443B2 and US11155872B2). B. Osmanodja and P.D. Walson have nothing to disclose. K. Budde has received research funds and/or honoraria from Abbvie, Alexion, Astellas, Astra-Zeneca, Bristol-Myers Squibb, CareDx, Fresensius, Hansa, Hexal, MSD, Natera, Novartis, Otsuka, Pfizer, Roche, Sandoz, Veloxis, and Vifor.
